NYSEMKT: HLSQTessera Defense And Homeland Security Inc Stock
$1.07-0.20 (-15.75%)
Updated Sep 14, 2026
HLSQ Price
$1.07
Fair Value Price
N/A
Market Cap
$2.86M
52 Week Low
$0.98
52 Week High
$122.93
P/E
0x
P/B
0.26x
P/S
10.8x
PEG
N/A
Dividend Yield
N/A
Revenue
$332.00k
Earnings
-$72.81M
Gross Margin
29.2%
Operating Margin
-21,520.78%
Profit Margin
-21,929.8%
Debt to Equity
0.97
Operating Cash Flow
-$18M
Beta
0.65
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
HLSQ Overview
BiomX Inc., formerly Chardan Healthcare Acquisition Corp., is a microbiome company. The Company is focused on developing both natural and engineered phage therapies. It develops therapies to target and destroy bacteria that affect the appearance of skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease (IBD), primary sclerosing cholangitis (PSC) and cancer. The Company discovers and validates bacterial targets and customizes phage compositions against the targets. Its pipeline includes BX001, BX002 and BX003. BX001 is a product candidate that improves the appearance of acne-prone skin. BX002 is a customized phage cocktail that eradicates bacterial targets associated with the onset of IBD. BX003 is a customized phage cocktail developed against specific strains of Klebsiella pneumoniae (Kp).
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine HLSQ's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -6.47% per year. Learn More
Zen Rating Component Grades
F
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
HLSQ
Ranked#246 of 459
Ranked#246 of 459
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $9.14 | A | |
| $6.85 | A | |
| $41.54 | A |
Be the first to know about important HLSQ news, forecast changes, insider trades & much more!
HLSQ News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how HLSQ scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
HLSQ is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
HLSQ is good value based on its book value relative to its share price (0.26x), compared to the US Biotechnology industry average (5.35x)
P/B vs Industry Valuation
HLSQ is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more HLSQ due diligence checks available for Premium users.
Valuation
HLSQ price to earnings (PE)
For valuing profitable companies with steady earnings
Company
0x
Industry
8.25x
Market
43.6x
HLSQ price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.26x
Industry
5.35x
HLSQ is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
HLSQ's financial health
Profit margin
Revenue
$332.0k
Net Income
-$3.8M
Profit Margin
-1,136.1%
HLSQ's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
HLSQ's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$28.2M
Liabilities
$10.6M
Debt to equity
0.97
HLSQ's short-term liabilities ($10.18M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
HLSQ's short-term assets ($2.42M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
HLSQ's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
HLSQ's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.2M
Investing
-$556.0k
Financing
$905.0k
HLSQ's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
HLSQ vs Biotech Stocks
Tessera Defense And Homeland Security Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.